Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
about
Blood pressure lowering efficacy of renin inhibitors for primary hypertensionCan Aliskiren be Considered as a New Novel Drug for Hypertension?Renin inhibitorsAliskiren: the first renin inhibitor for clinical treatmentAliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trialsTreating hypertension while protecting the vulnerable islet in the cardiometabolic syndromeEfficacy of aliskiren/hydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach.Drug mechanisms to help in managing resistant hypertension in obesityImpact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trialRole of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors.Blood pressure lowering efficacy of renin inhibitors for primary hypertension.Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.Central Pressure and Biomarker Responses to Renin Inhibition with Hydrochlorothiazide and Ramipril in Obese Hypertensives: The ATTAIN Study.Aliskiren: An orally active renin inhibitor.Role of aliskiren in blood pressure control and renoprotectionFirst-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination.Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pillEffectiveness of Valsartan/Amlodipine Single-pill Combination in Hypertensive Patients With Excess Body Weight: Subanalysis of China Status IIEffects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical TrialAntihypertensive treatment in patients with class 3 obesity.Direct renin inhibitors: a new approach to antihypertensive drug treatment.Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives.The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index.Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.Aliskiren: clinical experience and future perspectives of renin inhibition.AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1.Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapyRenin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension.Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.Blood pressure responder rates versus goal rates: which metric matters?Managing cardiovascular and renal risk: the potential of direct renin inhibition.Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implicationsIs there a future for direct renin inhibitors?Unmet needs in managing hypertension: potential role of direct renin inhibition.New class of agents for treatment of hypertension: focus on direct renin inhibition.A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment.Aliskiren in the treatment of hypertension and organ damage.
P2860
Q24241169-E0E83CC5-4B1B-408C-9745-1D439C81F35BQ26775106-DABB33E8-1BE4-4F1B-9FBE-BF6E0E0B2B4BQ27021804-79771C3F-2F41-427D-81BD-8CA2F78296B7Q28272666-CC03FD15-A488-4C65-8B71-91075200DC89Q28304657-8267E43C-016A-415C-9AFA-BEB1056A9574Q33840829-8E1E5035-8FF2-4B3B-9243-A2EA52065A9FQ33928738-BF47E936-6B3B-416E-AE82-41223F58C8C2Q34023578-A204564B-4743-48DB-A941-B9B006866DB8Q34222639-30B84CA8-48D9-47F4-A643-1F85EBAA50D9Q34608252-5502AAD3-5C4F-45ED-A3E2-D1CD363CE22CQ34681386-275DEB36-6F10-4770-AF9B-C1B60A1AFD07Q35000118-88AFF5F2-DE2B-4BF0-B401-4A407D0198D0Q35005395-E956607D-01CA-4AD6-AD12-DBBC09AF7566Q35013037-D6968419-514A-4219-9EDE-8A0097EAAFAFQ35026735-67044A31-21D2-4F8E-B09A-170A7F37C552Q35210508-4D986C53-6F84-4D4F-AD9B-1AF67A8D5A23Q35210533-3F92456A-3B29-4323-9060-591EB0314DD2Q36246020-A4192E40-D1B9-41CA-BAE4-72EE091973A0Q36258891-7FF626A5-7348-4527-B4B8-CB4B972409EEQ36328092-4B199B7F-A6FE-482E-A6A4-02777E5797E8Q36900799-A489B2E3-792C-457B-99D1-FBDA4D4C3804Q36979342-B7B748F7-5D26-4B56-B18E-5F63CFEA5E77Q37019887-DE43DB7F-8743-4A7B-8A6C-3F8A92FCE6E3Q37077205-39826B0B-6738-4FED-A116-1DF063579799Q37104856-DF5028B5-622F-4913-BBCB-8CE014376F49Q37111865-AA6A6003-B46D-4F03-8E4A-3367C02F36C1Q37142499-09B90543-FEAD-4F35-B84B-EC7D4EF55771Q37145704-B9B94498-7E40-400B-AE65-BAE995FA7079Q37199928-DBA831F1-1776-4E17-B8D4-6C84CD4B26C7Q37233102-9A2039BF-9900-449B-A0E5-6D0A4981228DQ37377943-D51B133B-4139-4E2C-B438-2B5213776575Q37418547-262F438B-FF17-4B9B-AC5C-1A23CCFE5C0CQ37510348-5AB06718-B5A5-4269-9D0B-10F4118339C8Q37518344-3DF9D78B-8C7C-47B1-B1DA-146ECA0C0F3EQ37727965-51B7FC99-DB3E-46EC-B9D6-5472CE73C2E4Q37750291-FFC4D331-D14C-4E6A-B9A4-E0D0D5344CECQ37801292-A9D0751C-29BE-43E0-80A0-01D472E8D64CQ37808079-E24B6D2F-1A2E-4B45-9E47-7968EF03E1C7Q37812140-3C8263FF-6F82-42F3-8739-097C0F31E1FAQ37812154-33945076-4580-4EEF-8BF3-46F810A1E7A7
P2860
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@en
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@nl
type
label
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@en
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@nl
prefLabel
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@en
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@nl
P2093
P1433
P1476
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
@en
P2093
Deborah L Keefe
Jens Jordan
Sam W Boye
Stefan Engeli
Stephanie Le Breton
P304
P356
10.1161/HYPERTENSIONAHA.106.084301
P407
P577
2007-03-12T00:00:00Z